Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00125632
Other study ID # O3877R
Secondary ID
Status Completed
Phase N/A
First received July 28, 2005
Last updated February 3, 2009
Start date August 2005
Est. completion date May 2008

Study information

Verified date December 2006
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The purpose of this study is to measure the effectiveness of a newly-designed oculomotor training program for patients with age-related macular degeneration.


Description:

Age-related macular degeneration (AMD) is currently among the top three leading causes of central vision loss in veterans (Chomsky et al., 1995) and is the most prevalent cause of blindness among veterans (37.2%, Quillen & Henry, 2000). The loss of central vision associated with these diseases has a profound impact on the quality of life of those affected, with many suffering depression. It is devastating to no longer be able to read a newspaper or recognize facial expressions. The use of preferred retinal locations (PRLs) to compensate for diseased foveae has offered hope to these patients in regaining some function. The investigators have developed a protocol that includes training in three major visual skills areas:

- visual awareness and eccentric viewing;

- reading eye movements; and

- processing of sequentially presented lexical information.

Module 1 focuses on making the patient aware of better vision at an eccentric location relative to degraded vision at the diseased fovea. Module 2 is focused on the improvement of the control of eye movements with the PRL. Module 3 is focused on reading practice without eye movements. These program curriculums and preliminary results are provided in the present proposal. The primary aim of this proposal is to quantitatively assess the relative effectiveness for improving reading and to establish the minimum training time need for skill improvement. Sixty patients with AMD who are already using a PRL will be selected to be similar in visual characteristics (e.g., visual acuity, contrast sensitivity, size of scotoma, duration of disease) and included in an experimental group. All patients in the experimental group will be trained with all three modules using a repeated measures - completely counterbalanced - design to control for training order effects. An additional 24 AMD patients will be recruited for a control group to be tested at the same time intervals as the experimental patients, but do not receive training between these assessment period intervals. The control group patients will be given the option to receive training following the assessment period. Both the experimental and the control patients will be assessed using the same outcome measures of reading (using MNRead Acuity Charts, the Pepper Visual Skills for Reading (VSR) Test, and the View Sentences Test). The performance of the experimental patients on the outcomes battery post-training will be compared to their pre-training performance on the same battery. Any change in performance of the experimental patients will be compared to the test-retest performance of the control patients. A questionnaire (the Veterans Administration Low Vision Visual Functioning Questionnaire) will also be administered to assess perceived abilities to perform everyday tasks before and following training. The control patients will also receive the questionnaire before and after their assessment period. In addition, the experimental patients will also be assessed on the exercises practiced during the module at the end of each daily training session to determine exactly when in the training protocol an improvement in performance on the exercises being trained has occurred. These daily performance measures provide for a finer scale for detecting performance changes. Statistical analyses will be conducted to answer the following key questions:

- What visual skills related to reading are trainable?

- Which methods are best for training these skills?

- What is the time course of visual skill improvement?

- Do the answers to these questions depend upon individual patient characteristics (e.g., age, disease severity, PRL location, cognitive factors)?

- Do patients who do not undergo training, but have repeated reading performance assessments, show improvements in reading skills?

Advances are being made in the area of retinal cell transplantation, gene therapy, and retinal prosthetics. When these techniques become part of standard clinical care, it is likely that the patients will require vision rehabilitation techniques to help them make sense of their potentially fragmented percepts. This research offers an evaluation of relative successes of the components of reading rehabilitation and will lead to the design of an efficient and effective composite training strategy.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date May 2008
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with a diagnosis of AMD

- An established preferred retinal locus

- Visual acuity of less than or equal to 20/70 and greater than or equal to 20/400 (in the better eye)

Exclusion Criteria:

- Those with other major ophthalmologic and neurologic disease; choroidal neovascularization ("wet" AMD); moderate to severe media opacities; and cognitive impairment

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind


Related Conditions & MeSH terms


Intervention

Procedure:
Eccentric Viewing Training for Reading


Locations

Country Name City State
United States Jesse Brown VA Medical Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

References & Publications (1)

Szlyk JP, Paliga J, Seiple W, Rabb MF. Comprehensive functional vision assessment of patients with North Carolina macular dystrophy (MCDR1). Retina. 2005 Jun;25(4):489-97. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Participants will be given the following assessment tests at 4 different times during the assessment (at baseline, after 6 weeks, after 12 weeks, and after 18 weeks): eye tracking measures, daily performance measures and reading measures.
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Terminated NCT03561922 - Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS N/A
Active, not recruiting NCT03872479 - Single Ascending Dose Study in Participants With LCA10 Phase 1/Phase 2
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Active, not recruiting NCT01736293 - Natural History of Eye Diseases Related to ABCA4 Mutations
Completed NCT03318549 - BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases N/A
Completed NCT04919473 - Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT03321253 - Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification N/A
Completed NCT01497379 - Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients N/A
Recruiting NCT04620876 - Bimodal and Coaxial High Resolution Ophtalmic Imaging N/A
Recruiting NCT03592017 - Performance of Long-wavelength Autofluorescence Imaging N/A
Completed NCT03150654 - The Effect of Laser Treatment on Macular Pigment of Eye in Cases With Diabetes N/A
Recruiting NCT04545736 - Oral Metformin for Treatment of ABCA4 Retinopathy Phase 1/Phase 2
Completed NCT00403195 - Clinical and Pathophysiological Description of Ocular Ischemic Syndrome N/A
Enrolling by invitation NCT06167642 - Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
Enrolling by invitation NCT02144103 - Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration Phase 1/Phase 2
Recruiting NCT06289452 - Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis Early Phase 1
Recruiting NCT06305416 - A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema Phase 3
Recruiting NCT02617966 - Rod and Cone Mediated Function in Retinal Disease

External Links